PI3K/p110α inhibition selectively interferes with arterial thrombosis and neointima formation, but not re-endothelialization: Potential implications for drug-eluting stent design

European Heart Journal

Volumn 35, Issue 12, 2014, Pages 808-820

  Holy, Erik W ^a,b,c   Jakob, Philipp ^a,b   Eickner, Thomas ^d   Camici, Giovanni G ^b   Beer, Jürg H ^c   Akhmedov, Alexander ^b   Sternberg, Katrin ^d   Schmitz, Klaus Peter ^d   Lüscher, Thomas F ^a,b   Tanner, Felix C ^a,b  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^b UNIVERSITY OF ZURICH   (Switzerland)

^c Kantonsspital Baden   (Switzerland)

^d UNIVERSITY OF ROSTOCK   (Germany)

Author keywords

Endothelium; PI3K p110 ; Re endothelialization; Restenosis; Thrombosis

Indexed keywords

2 (6 AMINO 9 PURINYLMETHYL) 5 METHYL 3 (2 METHYLPHENYL) 3H QUINAZOLIN 4 ONE; 9 (1 ANILINOETHYL) 7 METHYL 2 MORPHOLINOPYRIDO[1,2 A]PYRIMIDIN 4 ONE; ADENOVIRUS VECTOR; AS 602240; BETA GALACTOSIDASE; MESSENGER RNA; NITRIC OXIDE; PACLITAXEL; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3 KINASE INHIBITOR; PIK 75; PLASMINOGEN ACTIVATOR INHIBITOR 1; PLATELET DERIVED GROWTH FACTOR BB; PROTEIN P110; RAPAMYCIN; SMALL INTERFERING RNA; THROMBOPLASTIN; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; GUANOSINE TRIPHOSPHATASE; HYDRAZONE DERIVATIVE; IMMUNOSUPPRESSIVE AGENT; NF-KAPPA B KINASE; PROTEIN KINASE INHIBITOR; PROTEIN SERINE THREONINE KINASE; SULFONAMIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTERY THROMBOSIS; ARTICLE; CAROTID ARTERY INJURY; CAROTID ARTERY THROMBOSIS; CELL COUNT; CELL MIGRATION; CELL PROLIFERATION; CELL TYPE; CONTROLLED STUDY; DRUG ELUTING STENT; DRUG TARGETING; ENDOTHELIUM CELL; ENZYME ASSAY; ENZYME INHIBITION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN CELL; IN-STENT RESTENOSIS; MALE; MASS SPECTROMETRY; MOUSE; NEOINTIMA; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; VASCULAR ENDOTHELIUM; VASCULAR SMOOTH MUSCLE; ANIMAL; ANTAGONISTS AND INHIBITORS; BIOSYNTHESIS; C57BL MOUSE; CELL CULTURE; CHEMOTAXIS; DRUG EFFECTS; ENZYMOLOGY; METABOLISM; MONONUCLEAR CELL; RNA INTERFERENCE; THROMBOSIS;

ANIMALS; CELL PROLIFERATION; CELLS, CULTURED; CHEMOTAXIS; DRUG-ELUTING STENTS; ENDOTHELIUM, VASCULAR; GTP PHOSPHOHYDROLASES; HYDRAZONES; IMMUNOSUPPRESSIVE AGENTS; LEUKOCYTES, MONONUCLEAR; MALE; MICE, INBRED C57BL; MUSCLE, SMOOTH, VASCULAR; NEOINTIMA; NITRIC OXIDE; PACLITAXEL; PHOSPHATIDYLINOSITOL 3-KINASES; PLASMINOGEN ACTIVATOR INHIBITOR 1; PROTEIN KINASE INHIBITORS; PROTEIN-SERINE-THREONINE KINASES; RNA INTERFERENCE; RNA, SMALL INTERFERING; SIROLIMUS; SULFONAMIDES; THROMBOSIS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84897000826     PISSN: 0195668X     EISSN: 15229645     Source Type: Journal    
DOI: 10.1093/eurheartj/eht496     Document Type: Article

References (51)

1. Inoue T, Croce K, Morooka T, Sakuma M, Node K, Simon DI. Vascular inflammation and repair: implications for re-endothelialization, restenosis, and stent thrombosis. JACC Cardiovasc Interv 2011;4:1057-1066.
2. Morice MC, Serruys PW, Sousa JE, Fajadet J, Ban Hayashi E, Perin M, Colombo A, Schuler G, Barragan P, Guagliumi G, MolnàrF, Falotico R;RAVEL Study Group. Aran-domized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization. N Engl J Med 2002;346:1773-1780.
3. Schofer J, Schluter M, Gershlick AH, Wijns W, Garcia E, Schampaert E, Breithardt G; E-SIRIUS Investigators. Sirolimus-eluting stents for treatment of patients with long atherosclerotic lesions in small coronary arteries: double-blind, randomised controlled trial (E-SIRIUS). Lancet 2003;362:1093-1099.
4. Stone GW, Ellis SG, Cox DA, Hermiller J, O'Shaughnessy C, Mann JT, Turco M, Caputo R, Bergin P, Greenberg J, Popma JJ, Russell ME; TAXUS-IV Investigators. One-year clinical results with the slow-release, polymer-based, paclitaxel-eluting TAXUS stent: the TAXUS-IV trial. Circulation 2004;109:1942-1947.
5. Stone GW, Ellis SG, Cox DA, Hermiller J, O'Shaughnessy C, Mann JT, Turco M, Caputo R, Bergin P, Greenberg J, Popma JJ, Russell ME; TAXUS-IV Investigators. A polymer-based, paclitaxel-eluting stent in patients with coronary artery disease. N Engl J Med 2004;350:221-231.
6. Stone GW, Moses JW, Ellis SG, Schofer J, Dawkins KD, Morice MC, Colombo A, Schampaert E, Grube E, Kirtane AJ, Cutlip DE, Fahy M, Pocock SJ, Mehran R, Leon MB. Safety and efficacy of sirolimus-and paclitaxel-eluting coronary stents. N Engl J Med 2007;356:998-1008.
7. Ong AT, Mc Fadden EP, Regar E, de Jaegere PP, van Domburg RT, Serruys PW. Late angiographic stent thrombosis (LAST) events with drug-eluting stents. J Am Coll Cardiol 2005;45:2088-2092.
8. Nordmann AJ, Briel M, Bucher HC. Mortality in randomized controlled trials comparing drug-eluting vs. bare metal stents in coronary artery disease: a meta-analysis. Eur Heart J 2006;27:2784-2814.
9. Lüscher TF, Steffel J, Eberli FR, Joner M, Nakazawa G, Tanner FC, Virmani R. Drug-eluting stent and coronary thrombosis: biological mechanisms and clinical implications. Circulation 2007;115:1051-1058.
10. Garg S, Serruys PW. Drug-eluting stents: a reappraisal. Heart 2010;96:489-493.
11. Vanhaesebroeck B, Guillermet-Guibert J, Graupera M, Bilanges B. The emerging mechanisms of isoform-specific PI3K signalling. Nat Rev Mol Cell Biol 2010;11: 329-341.
12. Kok K, Geering B, Vanhaesebroeck B. Regulation of phosphoinositide 3-kinase expression in health and disease. Trends Biochem Sci 2009;34:115-127.
13. Hayakawa M, Kawaguchi K, Kaizawa H, Koizumi T, Ohishi T, Yamano M, Okada M, Ohta M, Tsukamoto S, Raynaud FI, Parker P, Workman P, Waterfield MD. Synthesis and biological evaluation of sulfonylhydrazone-substituted imidazo[1, 2-a]pyridines as novel PI3Kinase p110alpha inhibitors. Bioorg Med Chem 2007;15:5837-5844.
14. Holy EW, Stämpfli SF, Akhmedov A, Holm N, Camici GG, Lüscher TF, Tanner FC. Laminin receptor activation inhibits endothelial tissue factor expression. J Mol Cell Cardiol 2010;48:1138-1145.
15. Matter CM, Rozenberg I, Jaschko A, Greutert H, Kurz DJ, Wnendt S, Kuttler B, Joch H, Grünenfelder J, Zünd G, Tanner FC, Lüscher TF. Effects of tacrolimus or sir-olimus on proliferation of vascular smooth muscle and endothelial cells. J Cardiovasc Pharmacol 2006;48:286-292.
16. Yang Z, Ruschitzka F, Rabelink TJ, Noll G, Julmy F, Joch H, Gafner V, Aleksic I, Althaus U, Lüscher TF. Different effectsofthrombinreceptor activationonendothe-lium and smooth muscle cells of human coronary bypass vessels. Implications for venous bypass graft failure. Circulation 1997;95:1870-1876.
17. Viswambharan H, Ming XF, Zhu S, Hubsch A, Lerch P, VergèresG, Rusconi S, Yang Z. Reconstituted high-density lipoprotein inhibits thrombin-induced endothelial tissue factorexpression through inhibitionofRho A and stimulationofphosphatidylinositol 3-kinase but not Akt/endothelial nitric oxide synthase. Circ Res 2004;94:918-925.
18. Kumar A, Lindner V. Remodeling with neointima formation in the mouse carotid artery after cessation of blood flow. Arterioscler Thromb Vasc Biol 1997;17: 2238-2244.
19. Ota H, Eto M, Ako J, Ogawa S, Iijima K, Akishita M, Ouchi Y. Sirolimus and everolimus induce endothelial cellular senescence via sirtuin 1 down-regulation: therapeutic implication of cilostazol after drug-eluting stent implantation. J Am Coll Cardiol 2009;53: 2298-2305.
20. Knight ZA, Gonzalez B, Feldman ME, Zunder ER, Goldenberg DD, Williams O, Loewith R, Stokoe D, Balla A, Toth B, Balla T, Weiss WA, Williams RL, Shokat KM. A pharmacological map of the PI3-K family defines a role for p110alpha in insulin signalling. Cell 2006;125:733-747.
21. Bi L, Okabe I, Bernard DJ, Wynshaw-Boris A, Nussbaum RL. Proliferative defect and embryonic lethality in mice homozygous for a deletion in the p110alpha subunit of phosphoinositide 3-kinase. J Biol Chem 1999;274:10963- 10968.
22. Foukas LC, Claret M, Pearce W, Okkenhaug K, Meek S, Peskett E, Sancho S, Smith AJ, Withers DJ, Vanhaesebroeck B. Critical role for the p110alpha phosphoinositide-3-OH kinase in growth and metabolic regulation. Nature 2006;441:366-370.
23. Böse D, Leineweber K, Konorza T, Zahn A, Bröcker-Preuss M, Mann K, Haude M, Erbel R, Heusch G. Release of TNF-alpha during stent implantation into saphenous vein aortocoronary bypass grafts and its relation toplaque extrusion and restenosis. Am J Physiol Heart Circ Physiol 2007;292:2295-2299.
24. Wyss CA, Neidhart M, Altwegg L, Spanaus KS, Yonekawa K, Wischnewsky MB, Corti R, Kucher N, Roffi M, Eberli FR, Amann-Vesti B, Gay S, von Eckardstein A, Lüscher TF, Maier W. Cellular actors, Toll-like receptors, and local cytokine profile in acute coronary syndromes. Eur Heart J 2010;31:1457-1469.
25. Holy EW, Tanner FC. Tissue factor in cardiovascular disease: pathophysiology and pharmacological intervention. Adv Pharmacol 2010;59:259-292.
26. Jeong IK, Oh da H, Park SJ, Kang JH, Kim S, Lee MS, Kim MJ, Hwang YC, Ahn KJ, Chung HY, Chae MK, Yoo HJ. Inhibition of NF-kB prevents high glucose-induced proliferation and plasminogen activator inhibitor-1 expression in vascular smooth muscle cells. Exp Mol Med 2011;43:684-692.
27. Kim S, Garcia A, Jackson SP, Kunapuli SP. Insulin-like growth factor-1 regulates platelet activation through PI3-Ka isoform. Blood 2007;110:4206-4213.
28. Levitzki A. PDGF receptor kinase inhibitors for the treatment of restenosis. Cardio-vasc Res 2005;65:581-586.
29. Liu WF, Nelson CM, Tan JL, Chen CS. Cadherins, Rho A, and Rac1 are differentially required for stretch-mediated proliferation in endothelial versus smooth muscle cells. Circ Res 2007;101:44-52.
30. Schwartz RS, Chronos NA, Virmani R. Preclinical restenosis models and drug-eluting stents: still important, still much to learn. J Am Coll Cardiol 2004;44:1373-1385.
31. ′-kinase: stabilization and inhibition of the p110alpha catalytic subunit by the p85 regulatory subunit. Mol Cell Biol 1998;18:1379-1387.
32. Wu H, Shekar SC, Flinn RJ, El-Sibai M, Jaiswal BS, Sen KI, Janakiraman V, Seshagiri S, Gerfen GJ, Girvin ME, Backer JM. Regulationof Class IAPI3-kinases:C2domain-iSH2 domain contacts inhibit p85/p110alpha and are disruptedin oncogenic p85 mutants. Proc Natl Acad Sci USA 2009;106:20258-20263.
33. Torella D, Gasparri C, Ellison GM, Curcio A, Leone A, Vicinanza C, Galuppo V, Mendicino I, Sacco W, Aquila I, Surace FC, Luposella M, Stillo G, Agosti V, Cosentino C, Avvedimento EV, Indolfi C. Differential regulation of vascular smooth muscle and endothelial cell proliferation in vitro and in vivo by cAMP/PKA-activated p85alphaPI3K. Am J Physiol Heart Circ Physiol 2009;297:2015-2025.
34. Finn AV, Nakazawa G, Joner M, Kolodgie FD, Mont EK, Gold HK, Virmani R. Vascular responses to drug eluting stents: importance of delayed healing. Arterioscler Thromb Vasc Biol 2007;27:1500-1510.
35. Liu HT, Li F, Wang WY, Li XJ, Liu YM, Wang RA, Guo WY, Wang HC. Rapamycin inhibits reendothelialization after percutaneous coronary intervention by impeding the proliferation and migration of endothelial cells and inducing apoptosis of endo-thelial progenitor cells. Tex Heart Inst J 2010;37:194-201.
36. Jeanmart H, Malo O, Carrier M, Nickner C, Desjardins N, Perrault LP. Comparative study of cyclosporine and tacrolimus vs newer immunosuppressants mycopheno-late mofetil and rapamycin on coronary endothelial function. J Heart Lung Transplant 2002;21:990-998.
37. Long C, Cook LG, Hamilton SL, Wu GY, Mitchell BM. FK506 binding protein 12/12. 6 depletion increases endothelial nitric oxide synthase threonine495 phosphorylation and blood pressure. Hypertension 2007;49:569-576.
38. Kim JW, Suh SY, Choi CU, Na JO, Kim EJ, Rha SW, Park CG, Seo HS, Oh DJ. Six-month comparison of coronary endothelial dysfunction associated with sirolimus-eluting stent versus paclitaxel-eluting stent. JACC Cardiovasc Interv 2008; 1:65-71.
39. Steffel J, Latini RA, Akhmedov A, Zimmermann D, Zimmerling P, Lüscher TF, Tanner FC. Rapamycin, but not FK-506, increases endothelial tissue factor expression: implications for drug-eluting stent design. Circulation 2005;112:2002-2011.
40. Stähli BE, Camici GG, Steffel J, Akhmedov A, Shojaati K, Graber M, Lüscher TF, Tanner FC. Paclitaxel enhances thrombin-induced endothelial tissue factor expression via c-Jun terminal NH2 kinase activation. Circ Res 2006;99:149-155.
41. Camici GG, Steffel J, Amanovic I, Breitenstein A, Baldinger J, Keller S, Lüscher TF, Tanner FC. Rapamycin promotes arterial thrombosis in vivo: implications for evero-limus and zotarolimus eluting stents. Eur Heart J 2010;31:236-242.
42. Kim JW, Seo HS, Park JH, Na JO, Choi CU, Lim HE, Kim EJ, Rha SW, Park CG, Oh DJ. A prospective, randomized, 6-month comparison of the coronary vasomotor response associated with a zotarolimus-versus a sirolimus-eluting stent: differential recovery of coronary endothelial dysfunction. JAm Coll Cardiol 2009;53:1653-1659.
43. Serruys PW, Silber S, Garg S, van Geuns RJ, Richardt G, Buszman PE, Kelbaek H, van Boven AJ, Hofma SH, Linke A, Klauss V, Wijns W, Macaya C, Garot P, Di Mario C, Manoharan G, Kornowski R, Ischinger T, Bartorelli A, Ronden J, Bressers M, Gobbens P, Negoita M, van Leeuwen F, Windecker S. Comparison of zotarolimus-eluting and everolimus-eluting coronary stents. N Engl J Med 2010; 363:136-146.
44. Olson MF, Ashworth A, Hall A. Anessential role for Rho, Rac, and Cdc42 GTPases in cell cycle progression through G1. Science 1995;269:1270-1272.
45. Zhang LJ, Tao BB, Wang MJ, Jin HM, Zhu YC. PI3K p110a isoform-dependent Rho GTPase Rac1 activation mediates H2S-promoted endothelial cell migration via actin cytoskeleton reorganization. PLoS ONE 2012;7:e44590.
46. Cain RJ, Vanhaesebroeck B, Ridley AJ. The PI3K p110alpha isoform regulates endo-thelial adherens junctions via Pyk2 and Rac1. J Cell Biol 2010;188:863-876.
47. Graupera M, Guillermet-Guibert J, Foukas LC, Phng LK, Cain RJ, Salpekar A, Pearce W, Meek S, Millan J, Cutillas PR, Smith AJ, Ridley AJ, Ruhrberg C, Gerhardt H, Vanhaesebroeck B. Angiogenesis selectively requires the p110alpha isoform of PI3K to control endothelial cell migration. Nature 2008;453:662-666.
48. Besler C, Heinrich K, Rohrer L, Doerries C, Riwanto M, Shih DM, Chroni A, Yonekawa K, Stein S, Schaefer N, Mueller M, Akhmedov A, Daniil G, Manes C, Templin C, Wyss C, Maier W, Tanner FC, Matter CM, Corti R, Furlong C, Lusis AJ, von Eckardstein A, Fogelman AM, Lüscher TF, Landmesser U. Mechanisms underlying adverse effects of HDL on eNOS-activating pathways in patients with coronary artery disease. J Clin Invest 2011;121:2693-2708.
49. Papapetropoulos A, Garcia-Cardena G, Madri JA, Sessa WC. Nitric oxide production contributes to the angiogenic properties of vascular endothelial growth factor in human endothelial cells. J Clin Invest 1997;100:3131-3139.
50. Fukumura D, Gohongi T, Kadambi A, Izumi Y, Ang J, Yun CO, Buerk DG, Huang PL, Jain RK. Predominant roleof endothelial nitric oxide synthase in vascular endothelial growth factor-induced angiogenesis and vascular permeability. Proc Natl Acad Sci USA 2001;98:2604-2609.
51. Laufs U, Liao JK. Post-transcriptional regulation of endothelial nitric oxide synthase mRNA stability by Rho GTPase. J Biol Chem 1998;273:24266-24271.